M11.151

Clinical Causes: Genetic factors: inherited mutations that predispose individuals to crystal deposition Aging: increased risk with advancing age, especially over 60 Joint trauma or injury that may predispose to crystal deposits Metabolic conditions such as hyperparathyroidism or hemochromatosis Other underlying diseases affecting cartilage metabolism

Key Symptoms: Joint pain, especially during movement or after periods of inactivity Swelling and warmth around the affected joint Stiffness that limits range of motion in the hip Tenderness upon touch Potential episodes of acute joint inflammation Possible recurrence of symptoms involving the same or other joints

Diagnosis Path: Diagnosis typically involves a combination of clinical evaluation and imaging. Key steps include: - Medical history review, focusing on familial patterns and symptom progression - Physical examination looking for swelling, tenderness, and range of motion - Imaging studies such as X-rays that reveal calcifications in the cartilage - Joint fluid analysis to identify calcium pyrophosphate crystals, confirming the diagnosis Laboratory tests might be performed to rule out other causes of joint symptoms and assess underlying metabolic conditions.

Treatment Protocols: Management of familial chondrocalcinosis primarily aims to reduce symptoms and improve joint function. Common approaches include: - Nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief - Corticosteroid injections directly into the affected joint to decrease inflammation - Physical therapy to maintain joint mobility and strength - Use of assistive devices or modifications in activity to reduce joint stress - Addressing underlying metabolic disturbances if identified - Surgical intervention may be considered in severe cases with significant joint damage Regular monitoring and early intervention can help prevent progression and improve quality of life.